Publications

Title	Date	PC3I Authors	Journal
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy	May 13, 2022	PC3I Authors Ronac Mamtani	JAMA Oncology
Correction to: Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma	June 2, 2022	PC3I Authors Ronac Mamtani	Journal of Cancer Research and Clinical Oncology
Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice	June 7, 2022	PC3I Authors Ronac Mamtani; Melina Marmarelis	Pharmacoepidemiology and Drug Safety
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality	July 9, 2022	PC3I Authors Ronac Mamtani	JNCI Cancer Spectrum
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer	August 9, 2022	PC3I Authors Melina Marmarelis; Ronac Mamtani	Clinical Lung Cancer
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022	August 10, 2022	PC3I Authors Ronac Mamtani	Journal of the National Comprehensive Cancer Network
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors	August 29, 2022	PC3I Authors Kerry Coughlin; Larry Shulman; Ronac Mamtani	JAMA Network Open
Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden	November 13, 2022	PC3I Authors Ronac Mamtani; Daniel Lee	Urologic Oncology
Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy	December 22, 2022	PC3I Authors Daniel Lee; Ronac Mamtani	BJU International
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study	February 23, 2023	PC3I Authors Ronac Mamtani	BJUI Compass
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval	February 23, 2023	PC3I Authors Ramy Sedhom; Ronac Mamtani	JAMA Oncology
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis	March 2, 2023	PC3I Authors Ronac Mamtani	Journal of Cancer Research & Clinical Oncology
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90	March 19, 2023	PC3I Authors Ronac Mamtani; Melina Marmarelis	Clinical Lung Cancer
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer	April 14, 2023	PC3I Authors Ronac Mamtani	JAMA Network Open
Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation	May 8, 2023	PC3I Authors Ronac Mamtani	Epidemiology
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer	June 4, 2023	PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani	JAMA Oncology
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens	July 14, 2023	PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis	Clinical Lung Cancer
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma	September 4, 2023	PC3I Authors Ronac Mamtani	Cancer Investigation
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial	October 2, 2023	PC3I Authors Ronac Mamtani	Nature Medicine
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma	October 18, 2023	PC3I Authors Ronac Mamtani	Frontiers in Oncology